Digital Structured Education With Behavioral Nudge Tools for Adults With Type 2 Diabetes: Multicenter Randomized Controlled Trial.

JMIR Mhealth UhealthSep 1, 2026 (epub)
Clinical ResearchEndocrinologyOpen access

Yan Lin, Yingchun Zeng, Kaining Chen et al.

✦ AI-curated · Sources linked

In 30 seconds

This multicenter randomized controlled trial evaluated a digital structured education program with behavioral nudge tools in 293 adults with type 2 diabetes. The intervention group showed significant improvements in hemoglobin A1c (HbA1c) by -0.38% compared to the control group at 12 weeks, indicating enhanced metabolic and psychological outcomes.

Key findings

  • Intervention group had a significant HbA1c reduction of -0.38% at 12 weeks compared to control.
  • Fasting blood glucose decreased by -0.75 mmol/L in the intervention group.
  • Weight loss in the intervention group was -0.84 kg compared to control.
  • Improvements in self-management behaviors and self-efficacy were significantly greater in the intervention group.

Why it matters

The study highlights the potential of digital education combined with behavioral nudges to improve diabetes management, suggesting a scalable approach to enhance patient outcomes in a chronic disease context.

Source

PubMed · PMID 42695340Free full text on PubMed Central

Published in JMIR Mhealth Uhealth. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Endocrinology

Clinical ResearchHematology

Ponatinib-Blinatumomab or Imatinib-Chemotherapy for Adult Ph-Positive ALL.

This multicenter, phase 3 randomized trial compared frontline ponatinib plus blinatumomab with imatinib plus chemotherapy in adults with Philadelphia-positive acute lymphoblastic leukemia.

N Engl J MedOct 15, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary
Clinical ResearchRheumatology

Ianalumab for the Treatment of Patients with Sjögren's Disease.

Two 52-week, double-blind, randomized, placebo-controlled phase III trials evaluated monthly or less frequent ianalumab in patients with active Sjögren's disease.

N Engl J MedOct 22, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text
Create my personalized digestSee plans

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.